In ALS and other neurological disorders such as epilepsy, a key component of increased excitability is believed to be a decrease in the release or receptor strength of the inhibitory neurotransmitter GABA
and discover how custom IV therapy can elevate your wellness journey.
She has received research funding from the National Health & Medical Research Council, Australian Research Council, University of Melbourne, Deakin University, Sanofi, Meat and Livestock Australia and Woolworths Limited and Honoraria from Novartis
(4) Yue X, Liu SL, Guo JN, Meng TG, Zhang XR, Li HX, Song CY, Wang ZB, Schatten H, Sun QY, Guo XP
Maximum tolerated dose evaluation of the AMPA modulator Org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selection